title: [Efficacy of cytoflavin in the treatment of hypoxic-ischemic lesions of the nervous system in 1-month old children with transient neonatal hypothyroidism].
abstract: OBJECTIVE
  To evaluate the efficacy of cytoflavin in the treatment of hypoxic-ischemic lesions of the nervous system in young infants with transient neonatal hypothyroidism.
  
  
  METHODS
  Authors analyzed the efficacy of cytoflavin in the treatment of cerebral ischemia in the combination with transient neonatal hypothyroidism in 89 newborns. The main group comprised 43 children treated with intravenous cytoflavin in dose 2 ml per 1 kg of body weight per day for five days; 46 newborns of the comparison group received basic therapy.
  
  
  CONCLUSIONS
  It was found that the moderate depression of motor activity and autonomic-visceral dysfunctions were the leading clinical neurological manifestations in these groups. In the main group, there was a significantly more rapid decline of hyperthyreotropinemia, indirect hyperbilirubinemia, reduced severity of cerebral ischemia by the results of neurosonography on the 5th or 6th day and regression of the main clinical symptoms compared to the control group. The positive neuroprotective and thyroid protective effect of cytoflavin, good tolerability and its compatibility with other drugs used in the standard treatment of hypoxic-ischemic lesions of the central nervous system were identified.
authors.affiliation: Penza Institute of Advanced Medical Studies, Penza.
authors.forename: V I
authors.initials: VI
authors.lastname: Strukov
authors.affiliation: Penza Institute of Advanced Medical Studies, Penza.
authors.forename: M N
authors.initials: MN
authors.lastname: Maksimova
authors.affiliation: Penza State University Medical Institute, Penza.
authors.forename: T A
authors.initials: TA
authors.lastname: Kuptsova
authors.affiliation: Filatov Penza Regional Children's Clinical Hospital, Penza.
authors.forename: S F
authors.initials: SF
authors.lastname: Lysev
authors.affiliation: Penza Institute of Advanced Medical Studies, Penza.
authors.forename: Yu G
authors.initials: YG
authors.lastname: Shcherbakova
mesh_terms: D000975:Antioxidants / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D003409:Congenital Hypothyroidism / Q000150:complications* / Q000503:physiopathology; D004338:Drug Combinations; D005260:Female; D005486:Flavin Mononucleotide / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007290:Inosine Diphosphate / Q000627:therapeutic use*; D008297:Male; D009043:Motor Activity; D009536:Niacinamide / Q000627:therapeutic use*; D013386:Succinates / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D004338:Drug Combinations; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate